Eiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment Conference
PALO ALTO, Calif, May 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 10:30 AM ET in Miami, Florida. Eiger will also host one-on-one meetings with investors at the conference.
A live webcast of the presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com. A replay of the presentation will be available on the website for at least 90 days.
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from the investigator sponsored Phase 3 TOGETHER study.
All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Wheelhouse Life Science Advisors
SVP, Corporate Affairs
SOURCE Eiger BioPharmaceuticals, Inc.